Positive Quality Intervention: Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

**Description:** This PQI is centered on erythropoietin stimulating agent (ESA) ineligibility in patients with myelodysplastic syndromes (MDS), as well as understanding when an MDS patient fails ESA treatment or has a suboptimal ESA response.

**Background:** MDS are chronic disorders of clonal hematopoiesis leading to peripheral cytopenias, primarily anemia, which can ultimately progress to bone marrow failure and acute myeloid leukemia. Patients suffering from MDS are stratified by the revised International Prognostic Scoring System (IPSS-R) into risk groups ranging from very low to very high risk (Tables 1 and 2 in Supplemental Information). The treatment of lower risk MDS is typically focused on optimizing patients’ quality of life and providing support for symptomatic anemia to avoid chronic transfusions and risk of iron overload. ESA agents, including epoetin and darbepoetin, are commonly used to treat MDS-associated anemia in lower risk disease, but patient response to these agents can be variable and impermanent. Additionally, luspatercept represents a first line treatment option for patient with MDS-associated anemia based on results of the Phase III COMMANDS trial.

**PQI Process:** Upon diagnosis or clinical review of a MDS patient, patient should be assessed for symptomatic anemia and evaluated for differential diagnosis and then should proceed through following algorithm.

**RS:** ring sideroblasts; **EPO:** erythropoietin; **ESA:** erythropoietin stimulating agent; **G-CSF:** granulocyte colony-stimulating factor **IST:** immunosuppressive therapy.

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 3.14.23
• Luspatercept is indicated for the treatment of anemia in ESA naïve adult patients with very low- to intermediate-risk MDS who may require regular RBC transfusions
  o Inject 1mg/kg once every 3 weeks subcutaneously
  o Dose should be increased to 1.33mg/kg and then to 1.75mg/kg if transfusion was required since last assessment and should not be increased if less than 6 weeks have passed
• Consider luspatercept at first-line, or for patients who are ESA ineligible with no del(5)q
  o ESA Ineligible patients
    ▪ Del(5)q – these patients are also ineligible for luspatercept – consider lenalidomide
    ▪ EPO levels >500 regardless of RS status
• If considering an ESA
  o Generally, administration of ESAs yields an erythroid response; at least 1.5 g/dL increase in hemoglobin or decrease in need for RBC transfusion, in 20-60% of MDS patients with anemia1,4
  o Factors considered to be predictive of favorable response of MDS anemia to ESA agents include low baseline endogenous erythropoietin (EPO) levels (< 500 mU/mL, but preferably < 200 mU/mL), low (< 2 per month) or no RBC unit transfusion requirement, and disease cytogenetics, namely absence of del(5q) and less than 2 somatic mutations1,4,5,10
  o Conversely, patients with del(5q) disease, serum EPO levels > 500 mU/mL, or heavy transfusion dependence would commonly be considered ineligible for a trial of ESA therapy6,10
  o Primary resistance to ESA agents is possible, and, even if these patients do have an initial response to ESA therapy, in up to 70% of cases this response tends to wane within 18 to 24 months4,7
• ESA Eligible patients
  o Characteristics
    ▪ No del(5)q
    ▪ EPO levels < 500
    ▪ ESAs can be used regardless of RS status
  o Recommended starting dose of ESA
    ▪ Epoetin alfa or biosimilar 40,000–60,000 units subcutaneously 1–2 times per week or
    ▪ Darbepoetin alfa 150–300 mcg subcutaneously weekly to every other week
  o Assessment for ESA response by 6 to 8 weeks of treatment4
    ▪ 1.5 g/dL rise in hemoglobin and/or
    ▪ Decrease in RBC transfusion requirements by 6-8 weeks of treatment
  o Target hemoglobin range 10 to 11 g/dL; not to exceed 11 g/dL1,7-9
  o If desired response not reached can consider add on therapy with agent such as lenalidomide or granulocyte-colony stimulating factor1,4,10

Patient-Centered Activities:
• If patient is to start on luspatercept for treatment of MDS anemia
  o Advise patient of risk of increased blood pressure especially if patient has baseline history of hypertension11
  o Advise patient on signs/symptoms of venous thromboembolism, stroke, and myocardial infarction and when to contact healthcare provider on proceed to ER for evaluation
  o Counsel patient on most common side effects
    ▪ Blistering, peeling, or loosenings of the skin, red skin lesions, severe acne or a skin rash, sores or ulcers on the skin, or fever or chills
• If patient is decided to start on ESA for treatment of MDS anemia
  o Advise patient of risk of increased blood pressure especially if patient has baseline history of hypertension8-9
Advise patient on signs/symptoms of venous thromboembolism, stroke, and myocardial infarction and when to contact healthcare provider or proceed to ER for evaluation
Counsel patient to notify team of any upcoming surgical procedures as DVT prophylaxis is recommended in perisurgery patients
Educate that response to ESA therapy typically takes at least 6-8 weeks but can take up to 12 weeks
Counsel patient regarding risk of cutaneous reactions including rash but also severe reactions such as erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)

References:
8. Procrit® (epoetin alfa) [prescribing information].
9. Aranesp (darbepoetin alfa)® [prescribing information].
11. Reblozyl® (luspatercept-aamt) [prescribing information].

Supplemental Information:
Table 1. Revised international prognostic scoring system (IPSS-R) in myelodysplastic syndrome

<table>
<thead>
<tr>
<th>Prognostic variable</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Cytogenetics</td>
<td>Very good</td>
</tr>
<tr>
<td>Bone marrow blast (percent)</td>
<td>≤ 2</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>≥10</td>
</tr>
<tr>
<td>Platelets (cells/microL)</td>
<td>≥100</td>
</tr>
<tr>
<td>Absolute neutrophil count (cells/microL)</td>
<td>≥0.8</td>
</tr>
</tbody>
</table>

Table 2. IPSS-R myelodysplastic syndrome risk groups and prognosis

<table>
<thead>
<tr>
<th>Risk group</th>
<th>IPSS-R score</th>
<th>Median overall survival (years)</th>
<th>Median time to 25 percent AML evolution (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very low</td>
<td>≤1.5</td>
<td>8.8</td>
<td>&gt;14.5</td>
</tr>
<tr>
<td>Low</td>
<td>&gt;1.5 to 3.0</td>
<td>5.3</td>
<td>10.8</td>
</tr>
<tr>
<td>Intermediate</td>
<td>&gt;3 to 4.5</td>
<td>3.0</td>
<td>3.2</td>
</tr>
<tr>
<td>High</td>
<td>&gt;4.5 to 6</td>
<td>1.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Very high</td>
<td>&gt;6</td>
<td>0.8</td>
<td>0.7</td>
</tr>
</tbody>
</table>